What question did this study set out to answer?

July 30, 2008Arthritis & RheumatismOpen Access

A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndrome

View Full Paper

Ask AI

Bookmark

Authors

RGRaphaela Goldbach‐ManskyNational Institutes of Health SSSharukh D. ShroffNational Institute of Arthritis and Musculoskeletal and Skin Diseases MWMildred WilsonNational Institutes of Health

Discussion

Member takes

Implication

Open-label trial shows rapid symptom relief and decreased inflammation with rilonacept in familial cold autoinflammatory syndrome, highlighting its potential as a targeted therapy.

Key Points

To evaluate the safety, tolerability, and clinical efficacy of the long-acting interleukin-1 inhibitor rilonacept in patients with familial cold autoinflammatory syndrome.
Conducted an open-label pilot trial in five patients with familial cold autoinflammatory syndrome monitored for up to 24 months.
Administered a 300-mg subcutaneous loading dose of rilonacept, re-treated upon clinical flare, and maintained patients on 100 mg/week with optional escalation to 160 mg/week and 320 mg/week.
Evaluated clinical symptoms, quality of life, and inflammatory biomarkers (ESR, hsCRP, SAA, and IL-6) at 3, 6, 9, 12, and 24 months compared to baseline.
All five patients achieved rapid clinical improvement in cold-induced rash, fever, and joint symptoms within days of rilonacept treatment.
Weekly maintenance doses of 100 mg significantly reduced key inflammatory markers: ESR (P < 0.01), hsCRP (P < 0.001), and SAA (P < 0.001), with dose escalation yielding further ESR reductions.
Rilonacept was well tolerated over two years with no drug-related serious adverse events, although weight gain was observed in two patients.

Cite This Study

Goldbach‐Mansky et al. (2008) studied this question.

synapsesocial.com/papers/6a171aa6c23c548e2a7bc2bd https://doi.org/10.1002/art.23620

View Full Paper

Ask AI

Bookmark

Implication

Open-label trial shows rapid symptom relief and decreased inflammation with rilonacept in familial cold autoinflammatory syndrome, highlighting its potential as a targeted therapy.

A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndrome

Discussion

Member takes

Implication

Key Points

Cite This Study

A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndrome

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider